NO20014822L - Kim¶rt humanisert antistoff eller fragment derav, samt anvendelse av samme - Google Patents

Kim¶rt humanisert antistoff eller fragment derav, samt anvendelse av samme

Info

Publication number
NO20014822L
NO20014822L NO20014822A NO20014822A NO20014822L NO 20014822 L NO20014822 L NO 20014822L NO 20014822 A NO20014822 A NO 20014822A NO 20014822 A NO20014822 A NO 20014822A NO 20014822 L NO20014822 L NO 20014822L
Authority
NO
Norway
Prior art keywords
fragment
human antibody
reshaped
same
humanized antibody
Prior art date
Application number
NO20014822A
Other languages
English (en)
Other versions
NO315239B1 (no
NO20014822D0 (no
Inventor
Martine Elisa Verhoeyen
Original Assignee
Imp Cancer Res Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20014822L publication Critical patent/NO20014822L/no
Application filed by Imp Cancer Res Tech filed Critical Imp Cancer Res Tech
Publication of NO20014822D0 publication Critical patent/NO20014822D0/no
Publication of NO315239B1 publication Critical patent/NO315239B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20014822A 1990-09-07 2001-10-04 Kim¶rt humanisert antistoff eller fragment derav, samt anvendelse av samme NO315239B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909019553A GB9019553D0 (en) 1990-09-07 1990-09-07 Specific binding agents
PCT/GB1991/001511 WO1992004380A1 (en) 1990-09-07 1991-09-05 Specific binding agents

Publications (3)

Publication Number Publication Date
NO20014822L true NO20014822L (no) 1993-05-05
NO20014822D0 NO20014822D0 (no) 2001-10-04
NO315239B1 NO315239B1 (no) 2003-08-04

Family

ID=10681827

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19930825A NO314595B1 (no) 1990-09-07 1993-03-05 Fremgangsmåte for fremstilling av et kim¶rt terapeutisk aktivt humanisert antistoff eller et terapeutisk aktivt fragment derav, DNA-sekvenssom koder for antistoffet, samt plasmid og stabil vertscellelinje som omfatterDNA-sekvensen
NO20014822A NO315239B1 (no) 1990-09-07 2001-10-04 Kim¶rt humanisert antistoff eller fragment derav, samt anvendelse av samme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19930825A NO314595B1 (no) 1990-09-07 1993-03-05 Fremgangsmåte for fremstilling av et kim¶rt terapeutisk aktivt humanisert antistoff eller et terapeutisk aktivt fragment derav, DNA-sekvenssom koder for antistoffet, samt plasmid og stabil vertscellelinje som omfatterDNA-sekvensen

Country Status (18)

Country Link
US (2) US6204366B1 (no)
EP (1) EP0483961B1 (no)
JP (2) JP3514456B2 (no)
KR (1) KR930702526A (no)
AT (1) ATE233279T1 (no)
AU (1) AU653167B2 (no)
BG (1) BG60716B1 (no)
CA (1) CA2090961C (no)
DE (1) DE69133200T2 (no)
DK (1) DK0483961T3 (no)
ES (1) ES2193129T3 (no)
FI (2) FI113873B (no)
GB (1) GB9019553D0 (no)
HU (2) HU9300609D0 (no)
NO (2) NO314595B1 (no)
RO (1) RO113432B1 (no)
UA (1) UA46691C2 (no)
WO (1) WO1992004380A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
CA2103887C (en) * 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
AU5615594A (en) * 1992-11-13 1994-06-08 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US6281335B1 (en) * 1993-10-08 2001-08-28 Coulter Corporation Hybridoma and anti-KC-4 humanized monoclonal antibody
US5792852A (en) * 1992-11-16 1998-08-11 Cancer Research Fund Of Contra Costa Polynucleotides encoding modified antibodies with human milk fat globule specificity
CA2149529C (en) * 1992-11-16 2006-05-02 Fernado J. R. Do Couto Peptides and anti-sense peptides with broad neoplastic specificity
JPH07203974A (ja) * 1994-01-13 1995-08-08 Tosoh Corp 癌特異的ムチンを認識する抗体の遺伝子断片等
EP0781847A1 (en) * 1995-11-06 1997-07-02 MERCK PATENT GmbH Humanized monoclonal antibody
CN1327388A (zh) * 1997-11-14 2001-12-19 欧洲细胞技术有限公司 诱导抗独特型反应增强的修饰抗体
GB2360771A (en) * 2000-03-28 2001-10-03 Antisoma Res Ltd Compounds for targeting
WO2001074905A1 (en) * 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
WO2002078613A2 (en) * 2001-04-02 2002-10-10 Purdue Pharma L.P. Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
GB0200657D0 (en) * 2002-01-12 2002-02-27 Antisoma Plc Cancer treatment
CA2488441C (en) * 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
WO2004007687A2 (en) * 2002-07-16 2004-01-22 Stuart Bussell Methods to construct multimeric dna and polymeric protein sequences as direct fusions or with linkers
JP2007501011A (ja) * 2003-08-01 2007-01-25 ジェネンテック・インコーポレーテッド 制限多様性配列を有する結合型ポリペプチド
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
EP1973951A2 (en) * 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP2627356B1 (en) 2010-10-13 2019-05-22 Janssen Biotech, Inc. Human oncostatin m antibodies and methods of use
JP2014510080A (ja) * 2011-03-09 2014-04-24 セントローズ, エルエルシー 細胞外標的化薬物複合体
RU2493165C1 (ru) * 2012-02-28 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок muc1, способ детекции белка muc1 с помощью наноантител
EP3373006A1 (en) 2012-04-30 2018-09-12 Biothera, Inc. Beta-glucan immunotherapeutic methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP1103623A1 (en) * 1987-01-07 2001-05-30 Imperial Cancer Research Technology Limited Human mucin core protein: nucleic acid probes, peptide fragments and antibodies thereto, and uses thereof in diagnostic and therapeutic methods
EP0623679B1 (en) * 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
WO1989007268A1 (en) * 1988-02-08 1989-08-10 John Muir Cancer & Aging Institute Monoclonal antibody specific to a novel mucin-like glycoprotein surface antigen on human carcinoma cells
JPH04501719A (ja) * 1988-11-10 1992-03-26 インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド ポリペプチド
ZA898777B (en) * 1988-11-17 1990-12-28 Univ Melbourne Monoclonal antibodies
US5075219A (en) * 1989-04-05 1991-12-24 John Muir Cancer & Aging Institute Monoclonal antibody which recognizes a specific glycoprotein of a human milk-fat globule membrane mucin antigen and said mucin antigen
KR970007782B1 (ko) * 1989-11-17 1997-05-16 유니레버 엔 브이 특이적 결합제

Also Published As

Publication number Publication date
HU9300609D0 (en) 1993-05-28
FI930984A0 (fi) 1993-03-05
AU653167B2 (en) 1994-09-22
HUT67796A (en) 1995-04-28
NO315239B1 (no) 2003-08-04
US20020086978A1 (en) 2002-07-04
BG97607A (bg) 1994-03-31
DE69133200D1 (de) 2003-04-03
FI113873B (fi) 2004-06-30
JPH06500468A (ja) 1994-01-20
FI930984A (fi) 1993-03-05
EP0483961B1 (en) 2003-02-26
DK0483961T3 (da) 2003-06-23
WO1992004380A1 (en) 1992-03-19
NO20014822D0 (no) 2001-10-04
AU8495391A (en) 1992-03-30
JP2003061689A (ja) 2003-03-04
NO314595B1 (no) 2003-04-14
KR930702526A (ko) 1993-09-09
FI114611B (fi) 2004-11-30
ATE233279T1 (de) 2003-03-15
EP0483961A1 (en) 1992-05-06
DE69133200T2 (de) 2003-11-20
GB9019553D0 (en) 1990-10-24
NO930825D0 (no) 1993-03-05
BG60716B1 (en) 1996-01-31
CA2090961A1 (en) 1992-03-08
UA46691C2 (uk) 2002-06-17
JP3514456B2 (ja) 2004-03-31
ES2193129T3 (es) 2003-11-01
CA2090961C (en) 2004-01-20
US6204366B1 (en) 2001-03-20
RO113432B1 (ro) 1998-07-30
NO930825L (no) 1993-05-05

Similar Documents

Publication Publication Date Title
NO20014822D0 (no) Kim¶rt humanisert antistoff eller fragment derav, samt anvendelse av samme
PT99934A (pt) Processo para a producao de um anticorpo anti-htnf alfa recombinante ou humanizado
BR9708910A (pt) Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento
ATE130029T1 (de) Hybridome, die monoklonale antikörper gegen neue mucin-epitope produzieren.
FI840219A0 (fi) Human-humanhybridom foer neoplasmer
DK154769C (da) Monoklonalt antistof, fremstilling heraf, hybridomacellelinie til anvendelse ved fremstilling heraf samt fremgangsmaader til anvendelse heraf
FI922220A (fi) Specifika bindemedel.
DE69334036D1 (de) Hybridom und humanisierter monoklonaler anti-kc-4-antikörper, dafür kodierende dnas und rnas, kit und diagnostische verfahren
NO944443D0 (no) Monoklonale antistoffer
ATE84069T1 (de) Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist.
Orthner Parental Work and Early Adolescence
DK182188A (da) Humant tumorassocieret antigen
RU93033872A (ru) Связывающие агенты, антитела, клетки плазмиды, применение плазмид, днк, вариабельные области антител, композиция, применение связующих агентов
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
DK1414859T5 (da) Monoklonale anti-SSRP-1-antistoffer og hybridomer som producerer antistofferne

Legal Events

Date Code Title Description
MK1K Patent expired